Advanced search
1 file | 637.88 KB Add to list

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

(2014) LEUKEMIA RESEARCH. 38(5). p.557-563
Author
Organization
Keywords
PRACTICE GUIDELINES, Myelodysplastic syndromes, STATEMENT, ANEMIAS, UPDATE, OVERLOAD, DEFERASIROX, MANAGEMENT

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 637.88 KB

Citation

Please use this url to cite or link to this publication:

MLA
Delforge, Michel, Dominik Selleslag, Yves Beguin, et al. “Adequate Iron Chelation Therapy for at Least Six Months Improves Survival in Transfusion-dependent Patients with Lower Risk Myelodysplastic Syndromes.” LEUKEMIA RESEARCH 38.5 (2014): 557–563. Print.
APA
Delforge, Michel, Selleslag, D., Beguin, Y., Triffet, A., Mineur, P., Theunissen, K., Graux, C., et al. (2014). Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. LEUKEMIA RESEARCH, 38(5), 557–563.
Chicago author-date
Delforge, Michel, Dominik Selleslag, Yves Beguin, Agnès Triffet, Philippe Mineur, Koen Theunissen, Carlos Graux, et al. 2014. “Adequate Iron Chelation Therapy for at Least Six Months Improves Survival in Transfusion-dependent Patients with Lower Risk Myelodysplastic Syndromes.” Leukemia Research 38 (5): 557–563.
Chicago author-date (all authors)
Delforge, Michel, Dominik Selleslag, Yves Beguin, Agnès Triffet, Philippe Mineur, Koen Theunissen, Carlos Graux, Fabienne Trullemans, Dominique Boulet, Koen Van Eygen, Lucien Noens, Steven Van Steenweghen, Jan Lemmens, Pascal Pierre, Randal D’hondt, Augustin Ferrant, Dries Deeren, Ann Van De Velde, Wim Wynendaele, Marc Andre, Robrecht De Bock, André Efira, Dimitri Breems, Anne Deweweire, Kurt Geldhof, Wim Pluymers, Amanda Harrington, Karen MacDonald, Ivo Abraham, and Christophe Ravoet. 2014. “Adequate Iron Chelation Therapy for at Least Six Months Improves Survival in Transfusion-dependent Patients with Lower Risk Myelodysplastic Syndromes.” Leukemia Research 38 (5): 557–563.
Vancouver
1.
Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. LEUKEMIA RESEARCH. 2014;38(5):557–63.
IEEE
[1]
M. Delforge et al., “Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes,” LEUKEMIA RESEARCH, vol. 38, no. 5, pp. 557–563, 2014.
@article{5792825,
  author       = {Delforge, Michel and Selleslag, Dominik and Beguin, Yves and Triffet, Agnès and Mineur, Philippe and Theunissen, Koen and Graux, Carlos and Trullemans, Fabienne and Boulet, Dominique and Van Eygen, Koen and Noens, Lucien and Van Steenweghen, Steven and Lemmens, Jan and Pierre, Pascal and D'hondt, Randal and Ferrant, Augustin and Deeren, Dries and Van De Velde, Ann and Wynendaele, Wim and Andre, Marc and De Bock, Robrecht and Efira, André and Breems, Dimitri and Deweweire, Anne and Geldhof, Kurt and Pluymers, Wim and Harrington, Amanda and MacDonald, Karen and Abraham, Ivo and Ravoet, Christophe},
  issn         = {0145-2126},
  journal      = {LEUKEMIA RESEARCH},
  keywords     = {PRACTICE GUIDELINES,Myelodysplastic syndromes,STATEMENT,ANEMIAS,UPDATE,OVERLOAD,DEFERASIROX,MANAGEMENT},
  language     = {eng},
  number       = {5},
  pages        = {557--563},
  title        = {Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes},
  url          = {http://dx.doi.org/10.1016/j.leukres.2014.02.003},
  volume       = {38},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: